The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Targeting germline or somatic DNA repair defects (beyond BRCA) in pancreatic cancer with niraparib: A phase II study (NIRA-PANC).
 
Anup Kasi
Consulting or Advisory Role - Ipsen
Research Funding - Ability Pharma (Inst); Astellas Pharma (Inst); Bavarian Nordic (Inst); Cardiff Oncology (Inst); Cend Therapeutics (Inst); FibroGen (Inst); Geistlich Pharma (Inst); Novocure (Inst); Rafael Pharmaceuticals (Inst); TESARO (Inst)
 
Junqiang Dai
No Relationships to Disclose
 
Raed Moh'd Taiseer Al-Rajabi
Stock and Other Ownership Interests - Actinium Pharmaceuticals; Seagen
Consulting or Advisory Role - AstraZeneca; Bayer
Speakers' Bureau - Sirtex Medical
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Lexicon (Inst); Lilly (Inst); Merck (Inst); Sillajen (Inst)
 
Joaquina Celebre Baranda
Stock and Other Ownership Interests - Aprea Therapeutics; Forty Seven; Hylapharm; Merus NV; Moderna Therapeutics; MorphoSys; Zymeworks
Consulting or Advisory Role - Sanofi (Inst)
Research Funding - Astellas Pharma (Inst); Exelixis (Inst); Incyte (Inst); Lilly (Inst); Nektar (Inst); Pfizer (Inst); Regeneron (Inst); Sanofi (Inst); Tolero Pharmaceuticals (Inst); Xencor (Inst)
 
Anwaar Saeed
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Exelixis; Five Prime Therapeutics; Pfizer
Research Funding - Actuate Therapeutics (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Daiichi Sankyo/UCB Japan (Inst); Exelixis (Inst); Five Prime Therapeutics (Inst); innovent biologics (Inst); KAHR Medical (Inst); Merck Sharp & Dohme (Inst); Seagen (Inst)
 
Prabhakar Chalise
No Relationships to Disclose
 
Erin Carroll
No Relationships to Disclose
 
Shannon Bradbury
No Relationships to Disclose
 
Stephen Hyter
No Relationships to Disclose
 
Malgorzata Anna Witek
No Relationships to Disclose
 
Venkatadri Beeki
No Relationships to Disclose
 
Richard J. McKittrick
Employment - Oak Street Health (I)
 
Manidhar Reddy Lekkala
No Relationships to Disclose
 
Anusha Chidharla
No Relationships to Disclose
 
Sean Kumer
No Relationships to Disclose
 
Timothy Schmitt
No Relationships to Disclose
 
Stephen K. Williamson
Stock and Other Ownership Interests - Horizon Therapeutics; Iovance Biotherapeutics; Merus
Research Funding - Acceleron Pharma (Inst); Aleon Pharma (Inst); Astellas Pharma (Inst); Bayer Health (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Merck Serono (Inst); Nektar (Inst); Novartis (Inst); Pharmacyclics (Inst); Regeneron (Inst); Rogosin Institute (Inst); Sanofi (Inst); Seagen (Inst); Sotio (Inst)
 
Steven Soper
No Relationships to Disclose
 
Andrew K. Godwin
Stock and Other Ownership Interests - Clara Biotech
Honoraria - Sinochips Kansas
Consulting or Advisory Role - Biovica
Research Funding - BioFluidica (Inst); Clara Biotech (Inst); Predicine (Inst); VITRAC Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Provisional Patent application entitled - "WJMSC-Derived Small Extracellular Vesicle (sEVs) Enhance T Cell Suppression Through Checkpoint PD-L1" - Dr. Joseph McGuirk (applicant) (Inst)
 
Weijing Sun
Honoraria - Merck
Consulting or Advisory Role - AstraZeneca; Macrogenics; Taiho Oncology
Research Funding - AstraZeneca (Inst); Merck (Inst); Novella Clinical (Inst)